Treating patients with ocular hypertension: preserving sight or a waste of resources?
October 15th 2005In a point-counterpoint debate, David L. Epstein, MD, Duke University Medical Center, Durham, NC, advocated treatment for most ocular hypertensive patients, drawing an analogy to treatment of systemic hypertension.
Algorithmic formulations may help manage diabetic macular edema
October 15th 2005By its nature, diabetic macular edema (DME) is somewhat resistant to simple algorithmic formulations because of the multifactorial nature of the decision-making process and the host of new therapies that continually become available, explained Julia Haller, MD, during retina subspecialty day at the American Academy of Ophthalmology annual meeting.
October is World Blindness Awareness Month
October 15th 2005Recognizing October as World Blindness Awareness Month, EyeCare America?the public service foundation of the American Academy of Ophthalmology?encourages people to call its toll-free helpline to see if they are eligible for a free eye exam and up to 1 year of eye care at no cost.
Low-vision rehab covers more than physical needs
October 15th 2005Sun City West, AZ—The effects of low vision in elderly patients, who make up the majority of individuals affected, can be devastating. Visual impairments rank just behind arthritis and heart disease in terms of the impact on the elderly population. Low-vision rehabilitation is extremely helpful in allowing elderly patients, that is, one in four of those over age 75 years, to function as fully as possible by teaching them how to reorganize their environment and use low-vision technology.
Keep on the watch for internal fraud and abuse
October 15th 2005Fraud and abuse in the ophthalmologist's optical dispensary are difficult to detect. Once suspected or even discovered, it is even more difficult as well as time-consuming to assess what is really happening, and to what extent it is having a negative impact on the practice and dispensary.
SLT safer than ALT for open-angle glaucoma
October 15th 2005Reading, MA—Selective laser trabeculoplasty (SLT) is safer than argon laser trabeculoplasty (ALT) as a treatment for primary open-angle glaucoma (POAG) and offers the considerable advantage of not causing structural damage to the trabecular meshwork, said Mark A. Latina, MD.
Should all ocular hypertension cases be treated?
October 15th 2005Fort Lauderdale, FL—The management of ocular hypertension has been receiving increased attention since the publication of the Ocular Hypertension Treatment Study (OHTS) results in June 2002. An important area of controversy is what people with ocular hypertension, if anyone, should be treated in the face of treatment costs that approach more than $500/year and the risk of side effects.
Acanthamoeba keratitis potentially devastating
October 15th 2005Washington, DC—Maintaining an index of suspicion for Acanthamoeba infection in patients with keratitis is important, irrespective of a history of contact lens wear, because timely diagnosis and prompt treatment initiation are critical for a good prognosis, said John K. Dart, DM, FRCS, FRCOphth, at World Cornea Congress V.
Cryotherapy: A fall from grace, but not a crash
October 15th 2005That cryotherapy was to be useful in ophthalmology was first shown by Frederich Schoeler (1844-1918) in a German paper, in which he described application of cold carbonic acid crystals to the sclera of rabbits and showed that a lesion of the retina could be produced.
Chance of visual field loss relatively small with ONHD
October 15th 2005Iowa City—The rate of visual field loss in patients who had optic nerve head drusen (ONHD) was about 1.6% per year, approximately what would be expected for this condition, said Andrew G. Lee, MD, professor of ophthalmology, neurology, and neurosurgery at the University of Iowa Hospitals and Clinics, Iowa City.
Dexamethasone implant treats persistent macular edema
October 15th 2005Baltimore—The intravitreal bioerodable dexamethasone implant, evaluated in the Posurdex (Oculex Pharmaceuticals Inc./ Allergan) for Persistent Macular Edema Study, is a drug-delivery system that achieved the primary efficacy outcome, i.e., 2 lines or more improvement in vision 90 days after treatment, with the 700-mg dose.
Evidence-based medicine key to allocation of resources
October 15th 2005The problem with the use of the conversion factor is that physicians are penalized or rewarded based on a sustainable growth rate, which says that the rate of growth of services cannot exceed the growth of the gross domestic product.
Prospective trials needed for venous occlusive disease
October 15th 2005San Francisco—The search for a cure for venous occlusive disease continues but at a slow pace. The last 20 years have seen the introduction of promising medical and surgical therapy for venous occlusive disease. However, the results of prospective trials of these treatments are lacking.
Blue light-filtering IOL may be beneficial
October 15th 2005Montr?al—The blue light-filtering effects in the AcrySof Natural ultraviolet (UV) IOL (Alcon Laboratories) significantly reduce apoptosis of retinal pigment epithelium (RPE) cells induced by blue light compared with the conventional AcrySof filter lens. Implantation of a lens with a blue filter may be beneficial for patients who are at increased risk for the development of macular degeneration.